dc.contributor.author
Liberto, Valentina Di
dc.contributor.author
Mudò, Giuseppa
dc.contributor.author
Garozzo, Roberta
dc.contributor.author
Frinchi, Monica
dc.contributor.author
Fernández Dueñas, Víctor
dc.contributor.author
Iorio, Patrizia Di
dc.contributor.author
Ciccarelli, Renata
dc.contributor.author
Caciagli, Francesco
dc.contributor.author
Condorelli, Daniele F.
dc.contributor.author
Ciruela Alférez, Francisco
dc.contributor.author
Belluardo, Natale
dc.date.issued
2019-09-26T15:15:35Z
dc.date.issued
2019-09-26T15:15:35Z
dc.date.issued
2016-06-19
dc.date.issued
2019-09-26T15:15:35Z
dc.identifier
https://hdl.handle.net/2445/140855
dc.description.abstract
Guanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fphar.2016.00158
dc.relation
Frontiers in Pharmacology, 2016, vol. 7, p. 158
dc.relation
https://doi.org/10.3389/fphar.2016.00158
dc.rights
cc-by (c) Liberto, Valentina Di et al., 2016
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Trifosfat de guanosina
dc.subject
Guanosine triphosphatase
dc.title
The guanine-based purinergic system: the tale of an orphan neuromodulation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion